Cellebrite DI Ltd. (CLBT)
NASDAQ: CLBT · Real-Time Price · USD
17.47
-0.23 (-1.30%)
Nov 18, 2024, 4:00 PM EST - Market closed

Cellebrite DI Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Net Income
-316.92-81.1120.8171.45.78-1.88
Depreciation & Amortization
10.9910.519.697.075.884.08
Loss (Gain) From Sale of Investments
-2.35-1.11-0.37---
Stock-Based Compensation
26.371913.716.487.2712.76
Other Operating Activities
368.72116.24-120.44-69.58-2.13-1.67
Change in Accounts Receivable
-23.162.27-12.89-1.96-19.73-12.22
Change in Inventory
1.520.24-3.68-1.8-0.690.79
Change in Accounts Payable
-0.843.69-5.474.24-1.430.97
Change in Unearned Revenue
27.3146.1138.9721.847.7415.84
Change in Other Net Operating Assets
18.4-13.8-19.75-1.6123.83-2.55
Operating Cash Flow
110.03102.0620.5836.0566.5116.13
Operating Cash Flow Growth
17.09%395.98%-42.92%-45.79%312.26%-
Capital Expenditures
-7.65-5.23-6.9-5.11-6.18-6.21
Cash Acquisitions
-2.75---20-15.05-
Sale (Purchase) of Intangibles
-3.59-2.69-2.19-3--
Investment in Securities
-116.38-14.62-82.1573.3414.78-40.51
Investing Cash Flow
-130.36-22.54-91.2345.23-6.45-46.72
Issuance of Common Stock
18.4621.7713.972.311.490.14
Repurchase of Common Stock
-----0.09-0.81
Dividends Paid
----100-10-25
Other Financing Activities
-0.01--29.3--
Financing Cash Flow
18.4521.7713.97-68.4-8.5975.54
Foreign Exchange Rate Adjustments
1.160.59-1.64-0.750.7-0.07
Net Cash Flow
-0.72101.87-58.3312.1352.1644.88
Free Cash Flow
102.3896.8313.6830.9460.339.92
Free Cash Flow Growth
14.25%607.80%-55.79%-48.71%507.91%-
Free Cash Flow Margin
26.58%29.78%5.05%12.57%30.95%5.77%
Free Cash Flow Per Share
0.510.510.070.190.490.08
Cash Income Tax Paid
4.7510.059.058.162.913
Levered Free Cash Flow
-72.3481.5910.5136.2649.11-
Unlevered Free Cash Flow
87.4181.5910.5136.2649.11-
Change in Net Working Capital
-26.18-39.234.46-22.18-35.22-
Source: S&P Capital IQ. Standard template. Financial Sources.